- Home
- GLAS vs SLS Comparison
GLAS vs SLS Comparison
Compare GLAS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLAS | SLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | | United States |
| Employees | 357 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.1M | 924.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | GLAS | SLS |
|---|---|---|
| Price | $10.15 | $11.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 336.4K | ★ 7.2M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.24 | $1.39 |
| 52 Week High | $12.70 | $15.88 |
Technical Indicators
Market Signals| Indicator | GLAS | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 47.05 |
| Support Level | $9.36 | $3.91 |
| Resistance Level | $10.67 | $15.88 |
| Average True Range (ATR) | 0.63 | 1.21 |
| MACD | -0.08 | -0.41 |
| Stochastic Oscillator | 35.97 | 35.38 |
Price Performance
Historical ComparisonAbout GLAS Glass House Brands Inc. Subordinate Voting Shares
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.